Ascendis Pharma A/S (NASDAQ:ASND) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says
Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) had its target price raised by investment analysts at JPMorgan Chase & Co. from $168.00 to $200.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm presently has an “overweight” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s price objective […]
Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) had its target price raised by investment analysts at JPMorgan Chase & Co. from $168.00 to $200.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm presently has an “overweight” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s price objective […]
